Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar;19(115):59-63.
doi: 10.1183/09059180.00007309.

Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology

M Humbert  1
Affiliations
Review

Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology

M Humbert. Eur Respir Rev. 2010 Mar.

Abstract

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are two of the key subgroups of pulmonary hypertension. They are characterised by different risk factors. PAH can be associated with mutations in the gene encoding bone morphogenetic protein receptor type II (BMPR2), HIV infection, congenital heart disease, connective tissue disease (such as systemic sclerosis), and exposure to particular drugs and toxins including fenfluramine derivatives. In contrast, CTEPH can be associated with anti-phospholipid antibodies, splenectomy and the presence of a ventriculo-atrial shunt or an infected pacemaker. The first-line therapies used to treat PAH and CTEPH also differ. While medical therapy tends to be used for patients with PAH, pulmonary endarterectomy is the treatment of choice for patients with CTEPH. However, there are possible common mechanisms behind the two diseases, including endothelial cell dysfunction and distal pulmonary artery remodelling. Further research into these similarities is needed to assist the development of targeted pharmacological therapies for patients with inoperable CTEPH and patients who have persistent pulmonary hypertension after endarterectomy.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. These may also have benefits in patients with chronic thromboembolic pulmonary hypertension, although further research is necessary to establish this. NO: nitric oxide; sGC: soluble guanylate cyclise; cGMP: cyclic guanosine monophosphate; COX: cyclo-oxygenase; NOS: NO synthase; ECE: endothelin converting enzyme; AC: adenylate cyclase; cAMP: cyclic adenosine monophosphate; ET: endothelin; GMP: guanosine monophosphate; PDE: phosphodiesterase; PH: pulmonary hypertension. Reproduced from [13] with permission from the publisher.
FIGURE 2.
FIGURE 2.
The embolic hypothesis of chronic thromboembolic pulmonary hypertension (CTEPH). VTE: venous thromboembolism; PE: pulmonary embolism.
See this image and copyright information in PMC

References

    1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43–S54. - PubMed
    1. Newman JH. Pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 1072–1077. - PMC - PubMed
    1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425–1436. - PubMed
    1. Tuder RM, Abman SH, Braun T, et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S3–S9. - PubMed
    1. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030. - PubMed

MeSH terms